If you have sudden, severe tummy pain that is not going away, do not finish reading this page first. Contact NHS 111 or ask for an urgent GP appointment. If the pain is spreading to your back, or you have bloating that will not settle, a fast heartbeat or difficulty breathing, call 999 or go to A&E. Do not drive yourself. Take your medicines with you.
Acute pancreatitis is an uncommon side effect listed for Mounjaro. It can be serious when it occurs, although most people taking tirzepatide will not develop it. People search for this in several ways, including Mounjaro pancreatitis, pancreatitis Mounjaro and Mounjaro pancreatitis advice UK. They are usually asking the same two questions: how likely is it, and what symptoms should I look for? This page covers both and explains the current UK safety advice.
Key things to know
- Acute pancreatitis is listed as an uncommon adverse reaction for tirzepatide. In regulatory terms, uncommon means between 1 in 1,000 and 1 in 100 people.
- The MHRA strengthened the warnings for this class of medicines on 29 January 2026 after reports of severe, necrotising and fatal cases.
- A key warning sign is severe, persistent abdominal pain that may spread to the back, sometimes with nausea and vomiting.
- There is no established timeline for when pancreatitis may occur. Cases have been reported at different points during treatment.
- If pancreatitis is confirmed, MHRA advice is that treatment with this class of medicine should not be restarted.
- Gallstones and alcohol are major causes of acute pancreatitis in the UK and remain relevant when considering your overall risk.
When to get urgent help
This is the most important part of the page, so it comes first. The guidance below follows current NHS advice for acute pancreatitis.
| Situation | What to do |
|---|---|
| Sudden severe tummy pain that does not go away or keeps coming back, or comes with a high temperature or feeling hot, cold or shivery | Ask for an urgent GP appointment or contact NHS 111 |
| Sudden severe tummy pain that spreads to your back | Call 999 or go to A&E |
| Persistent bloating that will not settle, a fast heartbeat, or difficulty breathing alongside the pain | Call 999 or go to A&E |
| Skin around the belly button, waist or upper outer thigh looking blue or bruised, which can be harder to see on black or brown skin | Call 999 or go to A&E |
Do not drive yourself to A&E. Ask someone to take you or call 999 for an ambulance. Take your medicines with you so the medical team knows what you are taking.
If you are wondering whether a Mounjaro pancreatitis A&E visit is really necessary, it is safer to get medical advice when you have severe symptoms. Acute pancreatitis is usually assessed in hospital. You may need blood tests and, depending on your symptoms, a scan. Tell the medical team that you are using Mounjaro or another GLP 1 medicine. Also tell them where you obtained the medicine if it was supplied privately or online.
If you are searching for information about pancreatitis while you are experiencing severe abdominal pain, contact NHS 111 rather than relying on a website for an answer. Pancreatitis cannot be confirmed or ruled out from symptoms alone. A healthcare professional can assess your symptoms and decide whether you need further tests or treatment.
How common is pancreatitis with Mounjaro?
The product information for tirzepatide lists acute pancreatitis as an uncommon adverse reaction. In regulatory terms, uncommon means between 1 in 1,000 and 1 in 100 people. This is different from the term rare, which refers to a lower frequency of between 1 in 10,000 and 1 in 1,000 people.
Other pancreatic and digestive effects are also listed in the product information. Increases in the pancreatic enzymes lipase and amylase are listed as common. These enzymes can be measured with a blood test. Gallstones are also listed, and gallstones are a common cause of acute pancreatitis.
The MHRA received 1,296 Yellow Card reports of pancreatitis associated with GLP 1 and dual GLP 1/GIP medicines between 2007 and October 2025. However, a Yellow Card report records a suspected side effect and does not prove that the medicine caused it. Reporting is also voluntary, so these reports cannot be used to calculate the actual rate of pancreatitis among people taking these medicines. They show that a safety signal has been reported, rather than telling you your individual risk.
The research is not completely one sided. A large multicentre analysis published in the American Journal of Gastroenterology did not find an increased risk of acute pancreatitis among people with type 2 diabetes using GLP 1 receptor agonists. It also reported lower rates of complications among people who developed pancreatitis. However, this type of research does not remove the need to follow the safety warnings in the medicine information.
Is there a Mounjaro pancreatitis risk percentage?
There is no single percentage that can be used to describe the pancreatitis risk for every person taking Mounjaro in the UK. The licensed frequency category gives a range rather than one exact figure. Uncommon means between 0.1% and 1%.
It is also difficult to calculate a precise UK rate from Yellow Card reports because reporting is voluntary and the total number of people exposed to these medicines is not known from the reports.
Before starting Mounjaro, your prescriber will consider your medical history and other factors that may affect your treatment. This can include a history of pancreatitis, gallstones and alcohol use.
Some lifestyle measures may also help reduce the risk of conditions linked with pancreatitis. For example, maintaining a balanced diet and a healthy weight may help reduce the risk of gallstones. If you drink alcohol, follow current UK guidance on alcohol intake.
Do not try to diagnose pancreatitis yourself. If you develop severe or persistent abdominal pain, particularly if it spreads to your back or occurs with nausea or vomiting, seek urgent medical advice.
What the MHRA said in January 2026
On 29 January 2026, the MHRA issued a Drug Safety Update covering GLP 1 receptor agonists and dual GLP 1/GIP receptor agonists licensed in the UK. This includes tirzepatide alongside medicines containing dulaglutide, exenatide, liraglutide and semaglutide.
The product information for these medicines was updated to highlight the potential for severe acute pancreatitis, including reports of necrotising and fatal cases. Acute pancreatitis was already recognised as an uncommon adverse reaction. The update highlighted the possibility of severe cases and strengthened the safety advice.
Four points from the update are particularly important:
- Pancreatitis is a possible adverse reaction to these medicines, and severe cases have been reported.
- Seek urgent medical attention for severe, persistent abdominal pain that may spread to your back and may occur with nausea and vomiting.
- If pancreatitis is confirmed, do not restart a GLP 1 or GLP 1/GIP medicine unless specifically advised by an appropriate healthcare professional. The MHRA advises that these medicines should not be restarted after confirmed pancreatitis.
- Suspected side effects, including serious cases, can be reported through the Yellow Card scheme.
The MHRA also advises prescribers to use these medicines with caution in people who have a history of pancreatitis and to remain alert to possible symptoms.
How quickly can Mounjaro cause pancreatitis?
There is no established timeline for when pancreatitis may develop while taking Mounjaro. Cases have been reported at different points during treatment, and the product information does not give a specific period when the risk is known to be higher.
This is why you should not rely on a week by week schedule that claims there is a particular period when you are most likely to develop pancreatitis. There is not enough evidence to support a specific timeline.
It is also important to know the difference between common digestive side effects and symptoms that need urgent assessment. Nausea, vomiting and abdominal discomfort can occur with Mounjaro, particularly while your dose is being increased. However, sudden or severe abdominal pain that does not settle, especially when it spreads to your back, should not be assumed to be a normal side effect.
Mounjaro pancreatitis after dose increase
Many people ask whether increasing their Mounjaro dose can cause pancreatitis. There is no established rule saying that pancreatitis will occur after a dose increase, and the product information does not identify dose escalation as a specific trigger for pancreatitis.
Digestive side effects such as nausea, vomiting and abdominal discomfort can occur during treatment and may be more noticeable when the dose is increased. This can make it difficult to tell whether new symptoms are simply a side effect or something that needs medical attention.
The important thing is to look at the symptoms rather than assuming they are caused by the dose increase. Sudden, severe or persistent abdominal pain, particularly pain that spreads to the back or occurs with nausea and vomiting, needs urgent medical assessment.
If you are unsure whether your symptoms are serious, contact NHS 111 or your healthcare team for advice. Do not wait for the symptoms to become severe before seeking help.
Pancreatitis Mounjaro symptoms, and how they differ from ordinary side effects
Some symptoms of pancreatitis can overlap with the digestive side effects of Mounjaro. This can make it difficult to know when abdominal pain needs medical attention. Nausea, diarrhoea, vomiting, constipation and abdominal pain are all listed as common or very common side effects of tirzepatide, depending on the symptom. Abdominal pain on its own does not necessarily mean pancreatitis. The type, severity and pattern of the pain are important.
| Feature | Typical treatment side effect | Pattern that needs urgent assessment |
|---|---|---|
| Onset | May develop gradually, sometimes after a dose or meal | Sudden and does not settle |
| Severity | Uncomfortable but may be manageable | Severe or persistent |
| Location | May affect different areas of the tummy | Upper tummy pain that may spread to the sides or back |
| Position | Usually little difference with position | May feel worse when lying flat and better when leaning forward |
| Course | May improve over hours or days | Gets worse or does not settle |
| Other signs | May occur with nausea, vomiting or other digestive symptoms | Severe pain with persistent vomiting, a high temperature or a fast heartbeat |
Pain that is worse when lying flat and feels better when leaning forward can occur with acute pancreatitis. However, this symptom alone cannot confirm pancreatitis. If you have severe or persistent abdominal pain, particularly if it spreads to your back, seek medical advice rather than trying to diagnose the cause yourself.
Pancreatitis caused by gallstones can sometimes occur after eating, while alcohol is another recognised cause of acute pancreatitis. These details can be useful to tell the healthcare professional assessing you, but they cannot be used to diagnose pancreatitis on their own.
Mounjaro stomach pain: when to worry
Abdominal pain can occur while taking Mounjaro, so it is important to look at the overall pattern rather than assuming that every episode is pancreatitis.
Milder discomfort that comes and goes and then improves may be related to the digestive side effects of treatment. However, sudden or severe pain that does not settle, particularly if it spreads to the back or occurs with repeated vomiting, a high temperature or a fast heartbeat, needs urgent medical assessment.
If you are unsure about your symptoms, contact NHS 111 or your healthcare team. Do not wait until your next Mounjaro dose if you are experiencing severe or persistent abdominal pain.
Is it Mounjaro nausea or pancreatitis?
Nausea and vomiting are common side effects of tirzepatide and can also occur with acute pancreatitis. This means that nausea by itself cannot tell you which is causing your symptoms.
The type of pain you have is more important. Treatment related nausea may occur with other digestive side effects and can improve as your body adjusts to treatment. Nausea or vomiting together with sudden, severe abdominal pain that does not settle is more concerning and needs urgent medical assessment.
If you are unable to keep fluids down, seek medical advice. Ongoing vomiting can lead to dehydration and may need treatment regardless of the cause.
Mounjaro amylase lipase levels: what a blood test shows
People often search for Mounjaro side effects pancreas because increases in the pancreatic enzymes lipase and amylase are listed as common effects of tirzepatide. These enzymes can be measured with a blood test when pancreatitis is being investigated.
A raised enzyme level on its own does not confirm pancreatitis. Doctors usually consider your symptoms, blood test results and, where needed, imaging when making a diagnosis. A lipase or amylase level around three times the upper limit of normal can support a diagnosis when it occurs alongside the typical symptoms, but the exact assessment depends on the individual situation.
A small rise in these enzymes without symptoms does not necessarily mean you have pancreatitis. Equally, test results need to be considered alongside your symptoms rather than used on their own.
Routine monitoring of amylase and lipase is not generally required for everyone taking tirzepatide. Testing may be arranged when there is a clinical reason to investigate symptoms or another concern.
If you have had these tests for another reason and the results are raised, speak to the healthcare professional who requested them. Do not try to interpret the results on their own.
What acute pancreatitis actually is
The pancreas sits behind the stomach. It produces enzymes that help digest food and hormones, including insulin, that help control blood sugar.
Acute pancreatitis is sudden inflammation of the pancreas. It can happen for several reasons and may cause severe abdominal pain, nausea and vomiting.
In the UK, gallstones and alcohol are major causes of acute pancreatitis and together account for more than eight in ten cases. Other possible causes include certain medicines, injury during surgery, high blood calcium, high triglycerides and conditions such as lupus and mumps. Sometimes, doctors cannot identify a clear cause.
Many people with mild acute pancreatitis improve with treatment and may leave hospital within five to ten days. Treatment depends on how severe the condition is and may include fluids, nutrition and pain relief. Antibiotics are not routinely used for every case and may be given when there is a specific reason, such as an infection.
Some people develop complications, including pancreatic fluid collections or pancreatic necrosis. Repeated episodes can also contribute to chronic pancreatitis. Severe acute pancreatitis can be life threatening, which is why suspected cases may need hospital assessment and treatment.
Chronic pancreatitis and weight loss injections
Chronic pancreatitis is different from acute pancreatitis. It involves long term inflammation that can cause permanent damage to the pancreas. It can develop over time and may be linked to heavy alcohol use, repeated episodes of acute pancreatitis or other medical conditions.
Symptoms can include recurring abdominal pain, weight loss, greasy stools and problems digesting food. Some people can also develop problems controlling their blood sugar if the pancreas becomes damaged.
If you have a history of chronic or acute pancreatitis and are considering a weight loss injection, speak to your prescriber before starting treatment. MHRA advice recommends caution when these medicines are used in people with a history of pancreatitis.
Your prescriber can consider your medical history, current symptoms, other medicines and the reason for treatment before deciding whether Mounjaro is suitable for you.
The UK audit mentioned above found no cases of chronic pancreatitis among the small group of tirzepatide patients it reviewed. However, this was a small audit and cannot establish the safety of Mounjaro for everyone with a history of pancreatitis.
Mounjaro and alcohol
Questions about Mounjaro and alcohol pancreatitis risk need to be considered from two separate points of view. There is no established direct interaction between tirzepatide and alcohol. However, alcohol is a recognised cause of acute pancreatitis, and around a quarter of UK acute pancreatitis cases are linked to alcohol.
This does not mean that drinking alcohol while taking Mounjaro will cause pancreatitis. However, if you are concerned about your risk, it is sensible to discuss your alcohol intake with your prescriber, particularly if you have previously had pancreatitis.
The UK Chief Medical Officers advise that adults should not regularly drink more than 14 units of alcohol a week. If you drink up to 14 units, it is recommended that you spread this over three or more days and have several drink free days each week.
Alcohol may also make some digestive symptoms, such as nausea or reflux, more difficult to manage. If you have been advised to avoid alcohol because of a previous medical condition, follow that advice and speak to your healthcare professional if you are unsure.
Mounjaro, gallstones, pancreatitis and the rapid weight loss route
There is an important connection between gallstones, weight loss and pancreatitis. Gallstones are listed as an adverse reaction associated with tirzepatide, and gallstones are the most common cause of acute pancreatitis in the UK.
Rapid weight loss, regardless of how it is achieved, can also increase the risk of developing gallstones. In some cases, a gallstone can move into the bile duct and block the area where the pancreatic duct drains. This can trigger acute pancreatitis.
This does not mean that everyone taking Mounjaro will develop gallstones or pancreatitis. It is simply one of the possible pathways that doctors may consider when someone taking tirzepatide develops new abdominal pain.
If you develop new or severe upper abdominal pain while taking Mounjaro, particularly if it spreads to your back or comes with nausea or vomiting, seek medical advice. It may be important to check whether the symptoms are related to the gallbladder, pancreas or another condition.
For more information about Mounjaro, see tirzepatide for weight loss.
Can you take Mounjaro with a history of pancreatitis?
Two related questions often come up: can you take Mounjaro if you had pancreatitis years ago, and can you take Mounjaro if you have pancreatitis now or have recently had it? Both situations need to be assessed by a prescriber rather than decided from a website. However, the UK safety guidance gives a useful framework.
It is important to understand the difference between a history of pancreatitis and the situations where Mounjaro should not be used. If you had pancreatitis in the past from another cause, such as gallstones, MHRA advice is that GLP 1 and GLP 1/GIP medicines should be used with caution in people with a history of pancreatitis. Caution does not automatically mean that treatment is prohibited. Your prescriber can consider what caused the previous episode, whether that cause has been treated, your current health and whether Mounjaro is suitable for you.
The contraindications listed for tirzepatide are different. These include having a serious allergic reaction to tirzepatide or any of its ingredients. Mounjaro is also not recommended for people with a personal or family history of medullary thyroid carcinoma or for people with MEN 2, in line with the product information.
If you develop pancreatitis while taking a GLP 1 or dual GLP 1/GIP medicine, the advice is clearer. The MHRA advises that treatment should not be restarted if pancreatitis is confirmed. This applies across the class, so changing to another medicine in the same class is not a simple alternative.
Always tell your prescriber if you have had pancreatitis before. This gives them the information they need to assess whether Mounjaro is appropriate for you.
If injections are not suitable for you, there are other weight loss treatment options that you can discuss with a healthcare professional.
When to stop Mounjaro: pancreatitis suspected or confirmed
The product information advises that people taking Mounjaro should know the symptoms of acute pancreatitis. If pancreatitis is suspected, tirzepatide should be discontinued while the person is assessed. If pancreatitis is confirmed, the MHRA advises that treatment should not be restarted.
If you develop severe or persistent abdominal pain, particularly pain that spreads to your back, seek urgent medical attention. Tell the healthcare professional that you are taking tirzepatide and when you last had an injection. They can assess your symptoms and advise you about your treatment.
Do not ignore severe unexplained abdominal pain and continue taking Mounjaro simply because you are waiting for your next dose. At the same time, do not make long term changes to prescribed treatment based only on information from a website. If pancreatitis is suspected, seek medical assessment and follow the advice you receive.
Wegovy vs Mounjaro pancreatitis risk
There is no reliable way to rank Wegovy and Mounjaro based on their risk of pancreatitis. Both medicines have a recognised association with acute pancreatitis, and the MHRA strengthened the safety warnings for this group of medicines in January 2026.
The January 2026 MHRA update covered GLP 1 receptor agonists and dual GLP 1/GIP receptor agonists, including tirzepatide and semaglutide, as well as dulaglutide, exenatide and liraglutide. The update included advice about recognising symptoms, seeking urgent medical attention and not restarting treatment after confirmed pancreatitis.
The frequency figures listed for different medicines should also not be compared as though they come from one study. Clinical trials can involve different groups of people, treatment periods and methods of reporting side effects.
There is no simple head to head comparison that can tell you which medicine has the lower risk of pancreatitis. If you are choosing between Wegovy and Mounjaro, your prescriber can consider your medical history, other medicines, previous side effects and treatment goals.
Can you get pancreatitis after stopping Mounjaro?
Yes. Pancreatitis can occur for many reasons, whether or not someone has taken Mounjaro. The more specific question is whether stopping Mounjaro leaves an ongoing risk from the medicine itself.
Tirzepatide has a half life of around five days, so the amount of medicine in your body gradually falls after your last injection. It can take several weeks for most of the medicine to leave your system. There is currently no established evidence that stopping Mounjaro creates a delayed pancreatic effect long after the medicine has cleared.
There is another factor worth remembering. Gallstones can develop during periods of rapid weight loss and do not necessarily disappear when treatment stops. Gallstones can cause pancreatitis if they block the bile or pancreatic ducts.
If you develop severe abdominal pain weeks or months after stopping Mounjaro, do not assume that it is related to the medicine or that it cannot be pancreatitis. Seek medical advice and tell the healthcare professional that you previously used Mounjaro, including when you stopped it.
How to reduce the risk
Questions about how to prevent pancreatitis on Mounjaro or how to avoid pancreatitis on Mounjaro deserve a realistic answer. There is no way to remove the risk completely while taking a medicine that has pancreatitis listed as a possible adverse reaction. However, there are steps that may help you manage some of the known risk factors and recognise symptoms early.
- Tell your prescriber about any previous pancreatitis, gallstones or gallbladder surgery, high triglycerides, high blood calcium and your alcohol intake. This information can help them assess whether Mounjaro is appropriate for you.
- Follow UK guidance on alcohol intake and avoid binge drinking. Alcohol is a recognised cause of acute pancreatitis.
- Avoid trying to lose weight as quickly as possible. Rapid weight loss can increase the risk of gallstones, which are a major cause of acute pancreatitis. Follow the treatment and nutrition advice given by your healthcare professional.
- Only use Mounjaro supplied through a legitimate, regulated supply chain. Medicines obtained from unverified sources may not contain what the label says and may not have been stored correctly.
- Follow the dosing schedule given by your prescriber. Do not increase the dose yourself, take extra doses or use more than prescribed.
- Tell your prescriber about other medicines you take or plan to start. Some medicines are recognised as possible causes of pancreatitis, although medicine related pancreatitis is uncommon.
- Learn the warning symptoms rather than relying on a particular week or stage of treatment. Severe, persistent abdominal pain, especially when it spreads to the back or occurs with nausea and vomiting, needs urgent assessment.
These steps cannot guarantee that pancreatitis will not occur. They are intended to help you manage factors that may be within your control and recognise symptoms that need medical attention.
If pancreatitis is diagnosed
Treatment for acute pancreatitis usually takes place in hospital. Doctors may use blood tests and imaging to confirm the diagnosis and investigate the possible cause. Treatment can include intravenous fluids, nutrition and pain relief, depending on how severe the condition is.
The cause is also investigated because treating the underlying cause can help reduce the risk of further problems. For example, gallstones may require further treatment, while people whose pancreatitis is linked to alcohol may be offered support to reduce their alcohol intake.
If pancreatitis is confirmed while you are taking Mounjaro, tirzepatide should be discontinued. The MHRA advises that GLP 1 and GLP 1/GIP medicines should not be restarted after confirmed pancreatitis.
Any future approach to weight management should be discussed with a healthcare professional who knows your medical history. They can consider whether other options are appropriate for you.
Medical Disclaimer
This page provides general information about a recognised possible side effect of a prescription only medicine. It is not medical advice, a diagnosis or a substitute for assessment by a qualified healthcare professional.
This page cannot tell you whether your symptoms are caused by pancreatitis. If you have sudden or severe abdominal pain, particularly if the pain is persistent or spreads to your back, seek urgent medical advice.
Acute pancreatitis can require hospital assessment and treatment. If you are concerned about your symptoms, contact NHS 111 or an urgent GP service. Call 999 or go to A&E if you have severe symptoms such as difficulty breathing, a fast heartbeat or severe abdominal pain spreading to your back.
